Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000593674 | SCV000704702 | uncertain significance | not provided | 2016-12-23 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV003638683 | SCV004565184 | pathogenic | Glycogen storage disease due to phosphoglycerate kinase 1 deficiency | 2022-12-29 | criteria provided, single submitter | clinical testing | The PGK1 c.461T>C; p.Leu154Pro variant (rs1557247556) is reported in the literature as a confirmed de novo variant in one young adult male affected with phosphoglycerate kinase (PGK) deficiency (Ward). This variant is reported in ClinVar (Variation ID: 499279). The variant is also absent from the Genome Aggregation Database, indicating it is not a common polymorphism. The leucine at codon 154 is highly conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.981). Based on available information, this variant is considered to be pathogenic. REFERENCES Ward SK et al. Therapeutic Benefit of Blood Transfusion in a Patient With Novel PGK1 Mutation (c.461T>C [p.L154P]). J Pediatr Hematol Oncol. 2020 May. PMID: 30951021 |